A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated with Huntington Disease
What is the First-HD Trial?
First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months.
Who is running the First-HD Trial?
The First-HD Trial is being conducted by the Huntington Study Group (HSG) under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University). Approximately 30 HSG research sites across the United States and Canada will enroll about 90 people with HD. The study is sponsored by Auspex Pharmaceuticals, Inc. Please click here to find a participating HSG site near you.
Source: Huntington Study Group